scholarly article | Q13442814 |
P2093 | author name string | P Zhang | |
Y Wang | |||
T J Schall | |||
D A Johnson | |||
L C Seitz | |||
Y Zeng | |||
S Miao | |||
D J Dairaghi | |||
J C Jaen | |||
P Bekker | |||
A M Pennell | |||
J P Powers | |||
L S Ertl | |||
P2860 | cites work | The many roles of chemokines and chemokine receptors in inflammation | Q29618880 |
FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation | Q33446708 | ||
Microbes in gastrointestinal health and disease | Q33943525 | ||
Maraviroc for previously treated patients with R5 HIV-1 infection | Q34806062 | ||
Chemokines and chemokine receptors in rheumatoid arthritis | Q35031896 | ||
Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis | Q35553008 | ||
Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis | Q35636896 | ||
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. | Q36141697 | ||
Chemokines and leukocyte trafficking in rheumatoid arthritis | Q36354494 | ||
The role of chemokines in rheumatoid arthritis and osteoarthritis | Q36360715 | ||
Identification of C-C chemokine receptor 1 (CCR1) as the monocyte hemofiltrate C-C chemokine (HCC)-1 receptor | Q36401511 | ||
Scavenging roles of chemokine receptors: chemokine receptor deficiency is associated with increased levels of ligand in circulation and tissues | Q36742483 | ||
Chemokines and their receptors: drug targets in immunity and inflammation | Q36947059 | ||
Chemokine receptor antagonists: Part 1. | Q37481238 | ||
Chemokine receptor antagonists: part 2. | Q37481304 | ||
Anti-chemokine small molecule drugs: a promising future? | Q37683772 | ||
CCR1 antagonists: what have we learned from clinical trials | Q37763962 | ||
CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts | Q38334431 | ||
Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease | Q39675706 | ||
A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis | Q39763545 | ||
Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial | Q39850979 | ||
Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis | Q39874145 | ||
Proteolytic activation of alternative CCR1 ligands in inflammation | Q40419745 | ||
CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases | Q42605598 | ||
Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate | Q42956746 | ||
Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist | Q43248464 | ||
A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit | Q44223900 | ||
Prevalence of specific types of arthritis and other rheumatic conditions in the ambulatory health care system in the United States, 2001-2005. | Q44914209 | ||
Evaluation of the effect of the specific CCR1 antagonist CP-481715 on the clinical and cellular responses observed following epicutaneous nickel challenge in human subjects. | Q46323881 | ||
Chemokines and T lymphocytes: more than an attraction | Q47713299 | ||
Phase I evaluation of the safety, pharmacokinetics and pharmacodynamics of CP-481,715. | Q51465120 | ||
Blockade of chemokine signaling in patients with multiple sclerosis | Q57623592 | ||
Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity | Q73092605 | ||
Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: Implications for use of synovial sublining macrophages as a biomarker | Q81517383 | ||
CCR2 receptor blockade alters blood monocyte subpopulations but does not affect atherosclerotic lesions in apoE(-/-) mice | Q84741014 | ||
MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study | Q84966679 | ||
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | pharmacokinetics | Q323936 |
pharmacodynamics | Q725307 | ||
human subject research project | Q1331083 | ||
P304 | page(s) | 726-734 | |
P577 | publication date | 2011-03-30 | |
P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
P1476 | title | Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose. | |
P478 | volume | 89 |
Q38936733 | A novel CCR2 antagonist inhibits atherogenesis in apoE deficient mice by achieving high receptor occupancy |
Q37524080 | C5a receptor (CD88) blockade protects against MPO-ANCA GN |
Q27308841 | CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages |
Q39862548 | CCR1 antagonism attenuates T cell trafficking to omentum and liver in obesity-associated cancer. |
Q36177928 | CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease |
Q33816616 | CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice |
Q36170691 | Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study |
Q91199065 | Chemokines in rheumatic diseases: pathogenic role and therapeutic implications |
Q48268499 | Efficacy, safety and tolerability of the CCR1 antagonist BAY 86-5047 for the treatment of endometriosis-associated pelvic pain: a randomized controlled trial. |
Q53309302 | European League against rheumatism - selected presentation and poster a highlights June 11th to 13th 2013. |
Q38978556 | Identifying bias in CCR1 antagonists using radiolabelled binding, receptor internalization, β-arrestin translocation and chemotaxis assays |
Q57175297 | Inhibition of CCL3 abrogated precursor cell fusion and bone erosions in human osteoclast cultures and murine collagen-induced arthritis |
Q37432097 | International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors |
Q46441158 | Overcoming hurdles in developing successful drugs targeting chemokine receptors |
Q57787493 | Pyrrolone Derivatives as Intracellular Allosteric Modulators for Chemokine Receptors: Selective and Dual-Targeting Inhibitors of CC Chemokine Receptors 1 and 2 |
Q90642824 | Role of Chemokines and Chemokine Receptors in Rheumatoid Arthritis |
Q38647749 | Successes and failures of chemokine-pathway targeting in rheumatoid arthritis |
Q38148785 | Targeting CCL5 in inflammation |
Q39158831 | The Multifunctional Role of the Chemokine System in Arthritogenic Processes |
Q37948866 | Therapeutic potential of CCR1 antagonists for multiple myeloma. |
Q34076041 | Tumor progression locus 2 (Tpl2) kinase promotes chemokine receptor expression and macrophage migration during acute inflammation |
Q28742993 | Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis |
Search more.